Clinical trials: Older Adults With Cancer
Carcinoma, Renal Cell
Sorafenib in Elderly mRCC
This prospective, single arm, multi-center pilot study includes 120 mRCC patients over 65 years, no prior systemic treatment, determined to be candidates for systemic therapy by the investigator.
- Trial name
- NCT01728948
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Bayer
Plexiform Neurofibromas
Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
This phase II trial will test the hypothesis that inhibition of c-kit signalling pathways in pediatric patients with Neurofibromatosis Type I(NF-1) and progressing plexiform neurofibroma will result in objective reduction and/or…
- Trial name
- NCT02177825
- Testing
- Imatinib Mesylate
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- St. Justine's Hospital
Acute Myeloid Leukemia
Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients
A phase II trial to compare the efficacy and safety of nivolumab and intermediate dose cytarabine with or without haploidentical lymphocyte infusion.
- Trial name
- NCT03381118
- Testing
- Cytarabine, Nivolumab, G-CSF mobilized HLA-haploidentical donor PBSC
- Where
- Russia
- Volunteers
- 16 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Acute Leukemias
Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia
The study will evaluate the efficacy, safety and tolerability of two dosing schedules of LDE225 in patients with relapsed/refractory acute leukemia or elderly patients with untreated acute leukemia.
- Trial name
- NCT01826214
- Testing
- LDE225
- Where
- 23 sites in United States, Australia and 9 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Glioma
Hypofractionated Imrt (Vmat-Ra) For Elderly Patients With Newly Diagnosed High Grade Glioma
To assess the effect of IMRT using VMAT rapidarc approach, followed by adjuvant temozolomide on survival and quality of life in elderly, poor performance status patients with newly diagnosed HGG.
- Trial name
- NCT02099487
- Testing
- Radiation
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Clinico Humanitas
Breast Cancer
Elevate! : An Elderly Breast Cancer Cohort Study
This study is focused on understanding how the investigators can improve upon breast cancer and health outcomes for older participants with breast cancer.
- Trial name
- NCT03818087
- Testing
- Observational cohort
- Where
- 4 sites in United States
- Volunteers
- 253 people
- Sponsor
- Dana-Farber Cancer Institute
Glioblastoma
Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma
In newly diagnosed glioblastoma patients aged 70 years or older who are suitable for concurrent temozolomide, the optimal dose of radiation therapy is controversial .
- Trial name
- NCT05439278
- Testing
- Hypofractionated radiotherapy, Conventional radiotherapy, Temozolomide
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- Severance Hospital
Leukemia
S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PSC 833 may help chemotherapy drugs kill more cancer cells by making them more sensitive to the drugs.
- Trial name
- NCT00004217
- Testing
- filgrastim, sargramostim, cytarabine
- Where
- 90 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma, Non-Hodgkin, Lymphoma, Follicular
Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
This research study will only include two types of non-Hodgkin Lymphoma (NHL), follicular lymphoma or marginal zone lymphoma and participants will be age 70 or older.
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Low-Grade
- Trial name
- NCT01263418
- Testing
- Ofatumumab
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Elderly
Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)
The CARTIER study is a randomized, multicenter, open-label clinical trial comparing, in elderly patients with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies: primary (intensive…
- Conditions
- Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Elderly, Antineoplastic Agents, Cardiotoxicity
- Trial name
- CARTIER (NCT03711110)
- Testing
- Intensive cardiovascular monitoring, No intervention
- Where
- 14 sites in Spain
- Volunteers
- 514 people
- Sponsor
- Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Multiple Myeloma
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
The primary hypothesis of this study is that teclistamab SC in combination with daratumumab SC or lenalidomide will be safe and induce a high rate of VGPR or better in newly diagnosed multiple myeloma patients This is an…
- Trial name
- IFM2021-01 (NCT05572229)
- Testing
- Teclistamab, Daratumumab, Lenalidomide
- Where
- 22 sites in France
- Volunteers
- 74 people
- Sponsor
- University Hospital, Lille
Breast Cancer, Colorectal Cancer
Association of Capecitabine Pharmacokinetics and Toxicity With Aging
This is a multi-centre prospective non-interventional study designed to evaluate the effects of patient age on the pharmacokinetics of capecitabine and its metabolites 5'DFCR, 5'DFUR, and 5-FU.
- Trial name
- NCT03465202
- Testing
- Capecitabine
- Volunteers
- 100 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Multiple Myeloma
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
This protocol is a phase II multicenter, randomized, open label study designed to assess the efficacy and safety of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone (Dara-VCd) versus the association of…
- Trial name
- NCT03896737
- Testing
- Daratumumab plus Velcade Cyclophosphamide Dexamethasone, Velcade Thalidomide Dexamethasone
- Where
- 24 sites in Czechia, Greece and 1 more
- Volunteers
- 401 people
- Sponsor
- European Myeloma Network B.V.
Colorectal Cancer
Inclusion of Elderly Patients With Colorectal Cancer in Clinical Trials
Background: Inadequate representation of elderly cancer patients in randomized clinical trials (RCTs) leading to a lack of external validity thereby an uncertainty regarding benefit-risk balance of cancer treatment in elderly…
- Trial name
- SAGE (NCT01754636)
- Testing
- No intervention
- Where
- France
- Volunteers
- 707 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Stomach Neoplasms, Frail Elderly
Multimodal Prehabilitation To Improve The Clinical Outcomes Of Frail Elderly Patients With Gastric Cancer
The GISSG+2201 study was launched by Shandong Gastrointestinal Surgery Study Group (GISSG). The intention is to establish a multimodal prehabilitation protocol in frail elderly patients who undergo gastric cancer radical surgery…
- Trial name
- NCT05352802
- Testing
- Multimodal prehabilitation program, ERAS protocol
- Where
- China
- Volunteers
- 368 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Hematological Malignancies, Graft-versus-Host Disease (GVHD)
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis…
- Trial name
- PTCYGVHD (NCT06799195)
- Testing
- Attenuated-dose Cyclophosphamide, High-dose Cyclophosphamide, Sirolimus
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Nebraska
Infections, Papillomavirus
Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is a…
- Trial name
- NCT00369824
- Testing
- Different formulations of GSK Biologicals' HPV vaccine (580299), Menactra TM, Boostrix TM
- Where
- 50 sites in United States
- Volunteers
- 1,330 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
NSCLC, Stage III
Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy
This is a randomized, open-label, multicenter, phase II trial investigating the combination of thoracic radiotherapy plus Durvalumab in patients with locally advanced, unresectable NSCLC (stage III) that are unfit for…
- Trial name
- TRADE-hypo (NCT04351256)
- Testing
- Durvalumab Injection [Imfinzi], Thoracic Radiotherapy (TRT) conventionally, Thoracic Radiotherapy (TRT) hypofractionated
- Where
- 14 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Cancer
Clinical Study of Chemotherapy Combined With Chinese Medicine on Survival Affect of Elderly Patients With Lung Cancer
The purpose of this study is to observe the efficacy of chemotherapy combined with Traditional Chinese Medicine for elderly patients with advanced non-small-cell lung cancer, also to evaluate the adverse reaction and the…
- Trial name
- NCT01780181
- Testing
- TCM, Chemotherapy
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00022633
- Testing
- gemcitabine hydrochloride, paclitaxel
- Where
- 92 sites in United States
- Volunteers
- 65 people
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.